Abstract
Abstract
Background
Smoking and depression are closely related and form a vicious cycle. Yokukansan (YiganSan) is a polyherbal remedy that has the effect of calming neuropsychiatric symptoms such as anger and irritation. To examine the efficacy of Yokukansan during smoking cessation (SC) therapy in smokers with depressive tendencies but without major depressive disorders requiring pharmacotherapy.
Methods
A multicenter, double-blind, randomized, placebo-controlled, parallel-group comparison trial was conducted between June 2016 and May 2020 at 12 centers of the National Hospital Organization, Japan. This trial targeted smokers who first visited the SC outpatient clinics, did not receive any pharmacological treatment at the psychiatric or psychosomatic department, and scored 39 or more on the self-rating depression scale (SDS). Participants (n = 198) were randomly assigned to either the Yokukansan or placebo groups. The trial drug was initiated with the start of the SC treatment and continued for 12 weeks. The primary outcome was the high success rate of the SC treatment, and the secondary outcomes included changes in scores of the SDS and the Profile of Mood States (POMS) instrument.
Results
The success rate of the SC treatment was similar between the placebo (63%) and Yokukansan (67%) groups (P = .649). The SDS scores (placebo: mean difference [MD] = -3.5, 95% confidence interval [CI][-5.8, -1.2], d = 0.42; Yokukansan: MD = -4.6, 95%CI[-6.8, -2.3], d = 0.55), and the “tension-anxiety” POMS-subscale scores (placebo: MD = -1.6, 95%CI[-2.5, -0.7], d = 0.52; Yokukansan: MD = -1.6, 95%CI[-2.9, -0.3], d = 0.36) showed significant improvement in both groups after the SC treatment. However, “depression-dejection” improved in the Yokukansan group (MD = -1.9, 95%CI[-3.1, -0.7], d = 0.44) but not in the placebo group (MD = -0.1, 95%CI[-1.0, 0.7], d = 0.04). Significant improvement in “fatigue” was noted in the Yokukansan group (MD = -2.1, 95%CI[-3.4, -0.9], d = 0.47) but not in the placebo group (MD = -0.5, 95%CI[-1.8, 0.8], d = 0.11). The time × group interaction on the improvement in “depression-dejection” was significant (P = .019).
Conclusions
Yokukansan does not increase the SC treatment’s success rate but has additional positive effects on the psychological states due to the SC treatment in smokers with depressive tendencies but without apparent mental disorders.
Trial registration
ID: UMIN000027036. Retrospectively registered at UMIN on April 18, 2017.
Funder
National Hospital Organization
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine
Reference37 articles.
1. Agency for Healthcare Research and Quality. Treating tobacco use and dependence: 2008 Update—Clinical Practice Guideline. 2008. https://www.ahrq.gov/prevention/guidelines/tobacco/index.html.
2. Japanese Circulation Society, Japan Lung Cancer Society and Japanese Cancer Association. Standard procedures for smoking cessation therapy, sixth edition, 2014. http://www.j-circ.or.jp/kinen/anti_smoke_std/pdf/anti_smoke_std_rev6.pdf Accessed 10 Apr 2021.
3. Hasegawa K, Terashima S, Satoh N, Inoue M, Wada H, et al. Depressive state of patients on their initial visit to a smoking cessation clinic. Smoking Control Science. 2008;2(2):23–6 (in Japanese).
4. Wada H, Hasegawa K, Terashima S, et al. Self-rating depression scale score is a strong independent predictor of smoking cessation outcomes. Smoking Control Science. 2008;2:4–8 (in Japanese).
5. Sekiguchi K, Yamaguchi T, Tabuchi M, Ikarashi Y, Kaseet T. Effects of Yokukansan (YiganSan), a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid beta protein into mice. Phytother Res. 2009;23(8):1175–81. https://doi.org/10.1002/ptr.2777 (PMID: 19165748).